NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gains Ongoing comprehensive analysis of NVG-291's efficacy profile will support upcoming regulatory discussions, including seeking alignment with FDA on potential expedited approv
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-26 7:30 AM EDT | NervGen Pharma Corp.
OS Therapies Terminates Equity Line of Credit
New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it terminated its Equity Purchase Agreement (the "ELOC") with Square Gate Capital Master Fund, LLC — Series 3, effective August 26, 2025. "The recent success of our warrant exercise inducement and exchange offering provided the Company
2025-08-25 9:51 PM EDT | OS Therapies
Sona Provides Update on First-In-Human Clinical Trial
Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, is pleased to provide an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients. The treatment and follow-up assessments o
2025-08-25 9:14 AM EDT | Sona Nanotech Inc.
Defence Therapeutics Announces Debenture Units Financing
Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce a non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of up to $1,200,000 (the "Offering"). Each Unit will consist of (i) one $1,000 principal amount of
Biotechnology, Pharmaceuticals, Health
2025-08-22 8:30 PM EDT | Defence Therapeutics Inc.
Restart Life Sciences Provides Corporate Update on Strategy and Growth Initiatives
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") today announced that it has elected to cancel its previously planned LIFE financing, originally announced on July 8, 2025. The decision follows a review of evolving priorities and market opportunities. While the LIFE structure remains a useful tool, policy restrictions limit flexibility. With new opportunities under dis
Technology, Biotechnology, Health
2025-08-21 4:00 PM EDT | Restart Life Sciences Corp.
iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform
Woburn, Massachusetts--(Newsfile Corp. - August 21, 2025) - iSpecimen Inc. (NASDAQ: ISPC), an online marketplace for human biospecimens, today announced the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This critical achievement marks the installation of the Salestack platform and provisioning of modern infrastructure—laying the foundation for accelerated innovation, operational efficiency, and long-term scalability. Mil
2025-08-21 8:00 AM EDT | iSpecimen Inc.
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopha
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-21 7:30 AM EDT | NervGen Pharma Corp.
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights
Philadelphia, Pennsylvania--(Newsfile Corp. - August 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, is pleased to announce, following the acceptance of the Type C meeting request by the United States Food and Drug Administration (the "FDA"), the Company has submitted its queries in writing and expect to receive a response
Banking / Financial Services, Biotechnology, Investment Banking, Health
2025-08-21 7:30 AM EDT | Medicus Pharma Ltd.
Envoy Medical Secures Three New Patents, Strengthening Leadership in Fully Implantable Hearing Technology
White Bear Lake, Minnesota--(Newsfile Corp. - August 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new pa
Biotechnology, Healthcare and Hospitals
2025-08-20 8:00 AM EDT | Envoy Medical, Inc.
Hemostemix's Social Media for Investors and Florida's No-Option Patients
Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to its investor awareness and social media strat
Biotechnology, Pharmaceuticals, Health
2025-08-20 7:35 AM EDT | Hemostemix Inc.
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin, is pleased to announce it has entered into an agreement with MZ Investor Relations ("MZ"), an investor relations firm. MZ will provide Optimi with strategic support in capital markets advisory, corporate communications, and investor engagement. Under the te
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-08-20 7:30 AM EDT | Optimi Health Corp.
BioGene Therapeutics Inc. Appoints Dr. Francis Tavares, PhD., as Chief Technology Officer
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed of Dr. Francis Tavares as Chief Technology Officer effective on 19 August,
Biotechnology, Pharmaceuticals, Health
2025-08-20 7:00 AM EDT | PreveCeutical Medical Inc.
Bachem Expands Corporate Executive Committee to Include Chief Operations Officer Role
Bubendorf, Switzerland--(Newsfile Corp. - August 20, 2025) - The Bachem Group (SIX: BANB) announced today that Hans Van Hees, currently Chief Operations Officer Europe, will take on the role of Chief Operations Officer (COO) and join the Corporate Executive Committee (CEC) as of September 1, 2025. In this role, he will report to the CEO of Bachem, Thomas Meier, and will lead Bachem’s worldwide manufacturing network. Thomas Meier, who, in addition to his role as CEO, had
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-08-20 1:08 AM EDT | Bachem Holding AG
BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Kamal Albarazanji as Senior Director of Metabolic Research effective on
Biotechnology, Pharmaceuticals, Health
2025-08-19 7:00 AM EDT | PreveCeutical Medical Inc.
Hemostemix Announces Its AI Strategy
Calgary, Alberta--(Newsfile Corp. - August 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom Lawrence, Chief Commercialization Officer, Hemostemix, who completed exec
Biotechnology, Pharmaceuticals, Health
2025-08-19 6:54 AM EDT | Hemostemix Inc.
OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in preparation for Accelerated Approval submission following End of Phase 2 Meeting FDA End of Phase 2 Meeting scheduled for August 27, 2025 to review Phase 2b clinical trial in the prevention or delay of recurrent, pulmonary metastatic osteosarcoma Statistically significant 12-month Event Free Survival and interim 2-year
2025-08-19 6:00 AM EDT | OS Therapies
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted patent number ZL202180020893.4, titled "Purine Compounds for Treati
2025-08-18 5:05 PM EDT | Marvel Biosciences Corp.
Maxwell Biosciences Marks Scientist Appreciation Day With Renewed Call to Recognize Scientists
Austin, Texas--(Newsfile Corp. - August 18, 2025) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™, today celebrates Scientist Appreciation Day, an official company holiday that honors the essential contributions of scientists. The observance is a call to give scientists greater visibility and broader recognition of their work at a time when scientific research faces growing challenges in visibility
Biotechnology, Pharmaceuticals
2025-08-18 9:00 AM EDT | Maxwell Biosciences, Inc.
OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will report second quarter 2025 financial results ended June 30, 2025 and provide a business update on the morning of Tuesday, August 19, 2025. About OS Therapies OS Therapies is a clinical stage oncology company focused on the
2025-08-14 5:44 PM EDT | OS Therapies
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-14 4:15 PM EDT | Phio Pharmaceuticals Corp.